Recently, we have received the Supplementary Drug Application Approval from the NMPA for Libeisi® - calcium dobesilate tablets (0.5g). The product has passed the generic drug consistency evaluation, indicating that it has reached the level of consistency with the original drug in terms of quality and efficacy.

Adhering to the corporate philosophy of “Tech C&O  Persistent improving”, we are committed to creating high-quality generic drugs and contributing to the improvement of national health.